| ELEDON PHARMACEUT.DL-,001 |
| USA |
| Gesundheit |
| US28617K1016 / A2QL00 |
| 2TK (Frankfurt) / ELDN (NASDAQ) |
| FRA:2TK, ETR:2TK, 2TK:GR, NASDAQ:ELDN |
| - |
| https://eledon.com/ |
|
Eledon Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing precision therapies for patients with autoimmune diseases and organ transplant recipients. The primary goal ..
>Volltext.. |
| 187.55 Mio. EUR |
| 155.97 Mio. EUR |
| - |
| -74.4 Mio. EUR |
| -68.72 Mio. EUR |
| -1.04 EUR |
| 0.62 Mio. EUR |
| 3.16 Mio. EUR |
| -57.91 Mio. EUR |
| 6.53 |
| - |
| 24.25% |
| - |
| - |
| - |
| - |
| ELEDON |
| 12.03.26 |
|